Mendus has announced the launch of its chronic myeloid leukaemia (CML) programme for lead immunotherapy candidate, vididencel.
Redeye is optimistic about CML as a new indication and the VITAL-CML trial.
Yesterday, Terns Pharmaceuticals, a phase I/II CML company, accepted an acquisition offer from Merck.
Mendus has announced a new clinical collaboration with the Olivia Newton-John Cancer Research Institute (ONJCRI) to support the Phase Ib DIV...
Redeye comments on Mendus’ Q4 report. We have updated our valuation scenarios and present a new base case.
We have updated our investment view on Mendus following its expanded strategy for vididencel to chronic myeloid leukaemia (CML) and a broade...
Redeye comments on Mendus announcing a directed share issue.
Redeye provides its comment on Mendus’ Q3 2025 report.
Redeye updates its estimates and valuation after Mendus’ clinical strategy update.
Redeye comments on Mendus announcing a clinical strategy update, communicating its aim to address broader AML and CML populations in its vid...
Mendus’s Q225 results reflect a period of progress across the pipeline.
Redeye provides its comment on Mendus’ Q2 2025 report.
Mendus has reported its Q225 results. During the period, it made continued progress on the lead programme (vididencel in acute myeloid leuka...
Mendus has fortified its intellectual property (IP) profile for lead candidate, vididencel, with the granting of a new US patent covering it...
Redeye provides its comment on Mendus’ Q1 2025 report.
Redeye provides its comment on Mendus’ Q4 2024 report.
Mendus’s lead asset, vididencel, is fast approaching the pivotal stages of development in acute myeloid leukaemia (AML), with recent endorse...
Redeye adjusts its estimates after Institut Bergonié terminated the collaboration agreement to explore ilixadencel combination therapy as pa...
Redeye provides a brief comment on Mendus announcing that Institut Bergonié terminated the collaboration agreement with the company.
Mendus has reported positive top-line data for its Phase I ALISON trial, which is evaluating lead off-the-shelf cancer vaccine, vididencel, ...
Mendus continues to make headway with its lead programme assessing cancer vaccine vididencel as a potential maintenance therapy for acute my...
Redeye provides its comment on Mendus’ Q3 2024 report.
Mendus’s Q224 results reflect a period of steady progress across its clinical programmes.
Redeye provides its comment on Mendus’ Q2 2024 report.
Redeye briefly comments on Mendus announcing a collaboration with Institut Bergonié that involves treating up to 43 patients with ilixadence...
Mendus has announced a collaboration with Institut Bergonié, an established comprehensive cancer centre in France, to test ilixadencel in so...
Mendus recently presented positive data from two ongoing clinical studies, ADVANCE II and ALISON, at the EHA and ESMO conferences, respectiv...
With Mendus’s Q124 results, management recapped its clinical priorities, which are all progressing as expected.
Redeye provides its comment on Mendus’ Q1 2024 report.
Mendus has reported gross proceeds of c SEK69.1m from the exercise of series TO3 warrants that were issued in connection with the July 2023 ...
The Human Research Ethics Committee (HREC) has provided the green light to commence enrolment for Mendus’s AMLM22-CADENCE trial from April 2...
Mendus is forging ahead with vididencel, its primary clinical asset, aiming to address a market niche: the acute myeloid leukaemia (AML) mai...
Mendus has reported FY23 results, summarising an active period.
Redeye provides its comment on Mendus’ Q4 2023 report.
Mendus wrapped up FY23 with a clinical pipeline update.
Mendus has presented positive survival data for the ADVANCE II trial with its lead asset, vididencel, at the American Society of Hematology ...
Redeye comments on ADVANCE II’s principal investigator presenting an ADVANCE II survival update at ASH 2023.
Redeye notes Mendus announcing that ADVANCE II’s mRFS amounted to c30.
Mendus has entered into a collaboration with the Australasian Leukaemia & Lymphoma Group (ALLG) to initiate the ALLG AMLM22 CADENCE trial fo...
Mendus’s Q323 update was primarily focused on the clinical progression of its lead cancer vaccine, vididencel, which is being developed for ...
Redeye provides its comment on Mendus’ Q3 2023 report.
Mendus has announced that it has been granted three abstracts, including an oral presentation at the American Society of Hematology (ASH) 20...
Redeye notes Mendus announcing the publication of three abstracts ahead of presentations at ASH on 10-11 December 2023.
Mendus has announced that the FDA has granted Fast Track designation to its lead cancer vaccine, vididencel, as a potential maintenance ther...
Mendus has shared its Q223 report, including a financial update and overview of its clinical activities.
Redeye provides its comment on Mendus’ Q2 2023 report.
Following its previous announcement of secured financing commitments, Mendus has raised SEK227m through a rights issue and SEK90m through a ...
Mendus has provided an update on its development plans for its lead cancer vaccine, vididencel, primarily targeting the acute myeloid leukae...
Redeye comments on Mendus resolving the financing question hanging over its investment case and entering a manufacturing alliance with North...
Mendus has announced that it has secured financing commitments of c SEK317m, realised through an equity issue.
On the heels of Mendus’s recent Q123 results, we take a deep dive into the company’s lead cancer vaccine candidate, vididencel, and the acut...
Mendus’s Q123 report provided an insight into the strategic next steps for its lead cancer vaccine, vididencel (DCOne), as the company pursu...
Redeye provides its comment on Mendus’ Q1 2023 report.
Mendus recapped highlights of the positive clinical readouts from its ADVANCE II study in acute myeloid leukaemia (AML) in an investor updat...
FY22 was marked by several clinical milestones for Mendus, notably the positive survival data from the Phase II ADVANCE II study in acute my...
Redeye comments on Mendus’ Q4 2022 report, with the company presenting a way forward for lead candidate vididencel (formerly DCP-001).
Redeye comments on Mendus presenting ADVANCE II survival data at ASH 2022.
Mendus presented new positive survival data for the company’s cancer relapse vaccine, DCP-001, at the 64th American Society of Hematology (A...
Mendus has reported encouraging survival data from its Phase II ADVANCE II study, assessing its lead cancer vaccine candidate, DCP-001, as a...
In its Q322 report, Mendus highlighted key developments in the period, and some significant post-period events, as the company prepares to p...
Redeye comments on Mendus’ Q3 2022 report, as the company is approaching a crucial survival readout from its ADVANCE II trial in AML mainten...
Mendus has drawn down its first loan of SEK10m as part of the company’s binding commitment with its largest shareholder group, Van Herk Inve...
Redeye briefly comments on Mendus presenting first clinical data from its ALISON phase I trial with lead candidate DCP-001 in ovarian cancer...
Redeye comments on Mendus’ Q2 2022 report, following a quarter in which the company delivered solid final MRD data from ADVANCE II.
Redeye comments on Immunicum communicating interim data from its ADVANCE II trial, which we believe confirm positive top-line data that the ...
Immunicum specialises in the research and development of novel immunotherapies that target hard-to-treat tumours and tumour recurrence.
Redeye comments on Immunicum’s Q1 2022 report, which we judge came without any major surprises.
Redeye comments on Immunicum’s Q4 report and the company’s strategy outlook held yesterday evening.
Redeye comments on the Q2 report and expected upcoming news flow.
Redeye believes the update from the ILIAD trial confirms the strong safety profile of ilixadencel, notably now also in combination with chec...
